Therapeutic Implications of Blockers of Advanced Glycation End Products (AGEs)-their Receptor (RAGE) System

This publication has 54 references indexed in Scilit:

• RAGE Axis
  Arteriosclerosis, Thrombosis, and Vascular Biology, 2004
• The Role of Advanced Glycation End Products in Retinal Microvascular Leukostasis
  Investigative Opthalmology & Visual Science, 2003
• The AGE inhibitor pyridoxamine inhibits lipemia and development of renal and vascular disease in Zucker obese rats
  Kidney International, 2003
• Advanced glycation end products (AGE) and their receptor (RAGE) in the brain of patients with Creutzfeldt-Jakob disease with prion plaques.
  Neuroscience Letters, 2002
• Detection of Nε-(carboxymethyl)lysine (CML) and non-CML advanced glycation end-products in the anterior horn of amyotrophic lateral sclerosis spinal cord
  Amyotrophic Lateral Sclerosis, 2002
• Pyridoxamine inhibits early renal disease and dyslipidemia in the streptozotocin-diabetic rat
  Kidney International, 2002
• Therapeutic potential of AGE inhibitors and breakers of AGE protein cross-links
  Expert Opinion on Investigational Drugs, 2001
• Efficacy of benfotiamine versus thiamine on function and glycation products of peripheral nerves in diabetic rats
  Experimental and Clinical Endocrinology & Diabetes, 2001
• Advanced Glycation End Products in Alzheimer's Disease and Other Neurodegenerative Diseases
  The American Journal of Pathology, 1998
• Influence of advanced glycation end-products and AGE-inhibitors on nucleation-dependent polymerization of β-amyloid peptide
  Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 1997